On Jan. 13, 2023, LBP and Shanghai Akerman Medical Laboratory Co., Ltd jointly held the signing ceremony, which marks a deep strategic collaboration between the two parties in the fields of CRO-pharmaceutical enterprise central laboratory services and companion diagnosis. Through this strategic collaboration, the two parties will work closely in the fields of new drug research and development services, companion diagnosis and other advanced diagnosis and testing technologies while giving full play to their respective technical expertise and localized service solution, so as to further facilitate the clinical trials for innovative drugs.
Cai Xinglun, Secretary of the Board of Guangzhou LBP Medicine Science & Technology Co., Ltd., Vice General Manager of Shanghai LBP Diagnostics Technology Co., Ltd., Ge Junhui, General Manager and Ji Yifang, Sales Director of Shanghai Akerman Medical Laboratory Co., Ltd attended this signing ceremony and discussed the collaboration details and related business.
LBP and Shanghai Akerman Medical Laboratory Co., Ltd Hold the Signing Ceremony in Shanghai
Ge Junhui, General Manager of Shanghai Akerman Medical Laboratory Co., Ltd：We've already collaborated with LBP in many aspects. Both parties have laid a firm foundation in project communication and resources coordination. I'd like to thank LBP for its great support to Shanghai Akerman Medical Laboratory Co., Ltd and look forward to further strategic cooperation between us. By virtue of Shanghai Akerman Medical Laboratory Co., Ltd's excellent diagnostics resources and mature application technology system in pathology, as well as LBP's accumulation and commercial experience in IHC and FISH, we could provide global innovative drug enterprises with faster, more efficient and better solution of pathological central laboratory and jointly assist in innovative drug research and development in the world.
Cai Xinglun, Secretary of the Board of LBP：We look forward to deep collaboration with Shanghai Akerman Medical Laboratory Co., Ltd. We were deeply impressed by Shanghai Akerman Medical Laboratory Co., Ltd's technical expertise, innovative pathological technology and dedication to the industry. In combination with LBP's technical accumulation, profound channel resources and commercial market expansion, both parties will definitely integrate the resources in the fields of pharmaceutical enterprise services, new drug research and development and companion diagnosis, strengthen the competitive advantages in pharmaceutical enterprise service solution and win the first mover advantage in the context of rapid expansion of companion diagnosis market.
About Shanghai Akerman Medical Laboratory Co., Ltd
As the leader of third-party pathological diagnosis service industry in China, Shanghai Akerman Medical Laboratory Co., Ltd has enjoyed a good reputation for its continuous presence and technical innovation since its establishment. Its business covers in such fields as consultation for incurable diseases, routine pathology, IHC and molecular pathology. In addition, Shanghai Akerman Medical Laboratory Co., Ltd also provides medical institutions' department of pathology with customized solution and pharmaceutical enterprises with CRO pathological diagnosis services, and assist them improve the quality, efficiency and experience in precision medicine.
Shanghai Akerman Medical Laboratory Co., Ltd's CRO pharmaceutical enterprise service cycle covers prospective study, preclinical study and clinical study, including multi-color IHC/immunofluorescence research, methodological development validation, pathological diagnosis service, and pathologic complete response (pCR). These services can be customized according to pharmaceutical enterprises' demands and fully guarantee the CRO service quality.
About LBP
LBP has been dedicated to cancer screening and precision diagnosis products and service for 18 years. In particular, it has set up its product lines, including liquid-based cytology (LBP), polymerase chain reaction (PCR), immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). These product lines cover a variety of clinical diagnosis demands from cellular morphology, protein expression and genetic testing, as well as screening and diagnosis of dozens of cancers.
LBP has made full use of its existing technical and market channel resources to actively expand the products and services in pathologic AI, companion diagnosis and pathologic capacity construction and provide an integrated solution for pathologic diagnosis. In order to raise the level of "automation, standardization, digitization and intelligence" in the department of pathology, LBP has launched a series of digital pathology products. Among them, the pathologic medical image analysis and processing software, and fully automated digital slide scanning system have been certified and put on the market. In order to accurate medication for cancer patients, LBP has also actively expanded its pharmaceutical enterprise companion diagnosis business and already built a collaborative relationship with many domestic and foreign pharmaceutical enterprises, including AstraZeneca and Innovent Biologics.
